What it is and how it works
ABS-201 is an antibody designed by artificial intelligence to target the “Prolactin Receptor” (PRLR). Prolactin is a hormone that increases with age and stress, and it acts like a biological “stop sign” for hair follicles. In the normal hair cycle, follicles move from growth (anagen) to regression (catagen) and then rest (telogen). Research shows that high levels of prolactin act as a “catagen-promoting” signal, meaning it prematurely forces hair follicles to stop growing and enter the shedding phase. By blocking these receptors with a long-acting antibody, the treatment removes this “stop signal,” allowing the follicles to continue growing hair without the interruptions caused by age or stress-related hormone spikes.
The Science
The science behind this breakthrough reveals that prolactin doesn’t just stop growth; it actually triggers cell death (apoptosis) in the hair bulb and significantly inhibits the elongation of the hair shaft. In clinical trials, the AI-designed antibody showed a “directional readout” toward robust density improvements comparable to oral medications but with much more convenient dosing. Absci CEO Daniel Gil noted that this drug “has the potential to be the first new mechanism of action in androgenetic alopecia in nearly three decades”.
Availability and Benefit
ABS-201 is currently in Phase 1/2a clinical trials, with more definitive results expected in early 2027. While it is not yet for sale, people can benefit now by asking their doctor for a prolactin blood test. Identifying high levels of this hormone can help explain cases of “telogen effluvium” (sudden thinning) and guide current treatments while waiting for the antibody shots to reach the market (estimated 2028).